| 1 |
34486957 | From clinical trials to clinical practice: the use of everolimus and exemestane in the treatment of hormone receptor-positive metastatic breast cancer: real-world data. | 2022 May |
1 |
| 2 |
34740541 | Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors. | 2022 Feb |
2 |
| 3 |
35597619 | Everolimus and exemestane in hormone receptor positive advanced breast cancer: A comprehensive cancer center's experience. | 2022 Jun |
1 |
| 4 |
32951520 | Exemestane induced cholestatic liver injury - A case report. | 2021 Jun |
1 |
| 5 |
33230905 | Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy. | 2021 Feb |
2 |
| 6 |
34096894 | Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. | 2021 Jul 1 |
1 |
| 7 |
34196874 | Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. | 2021 Sep |
1 |
| 8 |
31618131 | Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. | 2020 Apr 20 |
3 |
| 9 |
31773503 | Everolimus-associated cytomegalovirus colitis in a patient with metastasized breast cancer: a case report. | 2020 Jul |
1 |
| 10 |
31932237 | A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer. | 2020 Apr |
1 |
| 11 |
32170637 | Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. | 2020 Oct |
2 |
| 12 |
32636632 | Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience. | 2020 |
1 |
| 13 |
32756099 | Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane. | 2020 Jul 31 |
1 |
| 14 |
32988969 | A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. | 2020 Dec 1 |
1 |
| 15 |
33151471 | Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis. | 2020 Dec |
1 |
| 16 |
30610588 | Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. | 2019 Apr |
4 |
| 17 |
30679318 | Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. | 2019 Jul |
1 |
| 18 |
30798641 | Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. | 2019 Mar |
1 |
| 19 |
31036468 | Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. | 2019 Jun |
2 |
| 20 |
29116433 | Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain. | 2018 Jun |
2 |
| 21 |
29124456 | Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. | 2018 Feb |
2 |
| 22 |
30700929 | Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer. | 2018 Dec |
1 |
| 23 |
28789401 | Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report. | 2017 Aug |
1 |
| 24 |
27210004 | Safety of mTOR inhibitors in breast cancer. | 2016 Aug |
1 |
| 25 |
26457979 | Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line. | 2015 |
1 |
| 26 |
23053261 | Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. | 2013 Jan |
2 |
| 27 |
23358971 | Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. | 2013 Apr 10 |
1 |
| 28 |
23425564 | Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. | 2013 May 1 |
1 |
| 29 |
23686401 | Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. | 2013 Aug |
1 |
| 30 |
23715630 | A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. | 2013 Jun |
2 |
| 31 |
24267730 | Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. | 2013 Dec |
1 |
| 32 |
22553196 | mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. | 2012 Oct |
1 |
| 33 |
21170551 | The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. | 2011 Jun |
1 |
| 34 |
19731013 | A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. | 2010 Jan |
1 |
| 35 |
18158620 | Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). | 2008 Nov |
2 |
| 36 |
18490163 | Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence? | 2008 Aug |
1 |
| 37 |
18282367 | Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors. | 2007 Dec |
1 |
| 38 |
15476902 | Role of aromatase inhibitors in the treatment of breast cancer. | 2004 Aug |
1 |